期刊文献+

人乳腺癌MDR1基因稳定沉默细胞的筛选及其生物学特性 被引量:2

Screening of stabilizing silencing MDR1 gene cell line of human breast cancer and its biological property
下载PDF
导出
摘要 目的筛选MDR1沉默的人乳腺癌细胞并比较其生物学特性。方法采用BLOCK-iT Lentiviral RNAi Expres-sion System生产表达MDR1基因shRNA的慢病毒载体,转导敏感人乳腺癌细胞MCF-7和耐阿霉素人乳腺癌细胞MCF-7/ADM,杀稻瘟菌素(blasticidin)筛选获得MDR1稳定沉默细胞MCF-7/RNAi和MCF-7/ADM/RNAi。定量RT-PCR检测MDR1mRNA表达,流式细胞术检测P-GP蛋白表达和功能,MTT法检测药物敏感性。结果经10 mg/L blasticidin筛选12 d获得MCF-7/RNAi和MCF-7/ADM/RNAi细胞。MCF-7、MCF-7/RNAi、MCF-7/ADM和MCF-7/ADM/RNAi细胞的MDR1mRNA相对表达水平分别为1、0.13、17.14和2.01;P-GP表达分别为(1.5±0.3)%、(1.2±0.2)%、(89.4±3.6)%和(16.3±1.9)%;细胞内Rh123的潴留分别为(92.4±3.1)%、(90.6±4.0)%、(13.6±1.6)%、(72.4±2.8)%;IC50值分别为0.90、0.92、19.61和4.04 mg/L。结论应用慢病毒载体稳定沉默MDR1基因可有效逆转人乳腺癌细胞耐药性。 Objective To screen human breast cancer cell line of MDR1 gene silenced and to compare its biological properties. Methods The lentiviral vector expressing MDR1 gene short hairpin RNA (shRNA) was produced by BLOCK-iT Lentiviral RNAi Expression System and then transducted into human breast cancer cell line MCF-7. Corresponding doxorubicin-resistant human breast cancer cell line MCF-7/ADM, which were selected subsequently with Blasticidin and MDR1 gene silenced cells including MCF-7/RNAi and MCF-7/ADM/RNAi were obtained. MDR1 mRNA level was measured by quantitative RT-PCR. The expression and function of P-glycoprotein(P-GP) were measured by flow cytometry. The drug sensitivity was evaluated by MTr assay. Results Two stably transducted selected cell lines, MCF-7/RNAi and MCF-7/ADM/RNAi, were obtained after being selected with 10 g/mL Blasticidin for 12 days. The relative expression levels of MDR1 mRNA in four cell lines,including MCF-7,MCF-7/ RNAi,MCF-7/ADM and MCF-7/ADM/RNAi were 1,0. 13,17.14 and 2. 01 respectively; P-GP expression levels were ( 1.5 ±0. 3 ) %, ( 1.2 ± 0. 2) %, (89.4±3.6 ) % and ( 16.3 ±1.9) %, respectively ; the retention of cellular rhodamine 123 were (92. 4 ± 3.1 ) %, (90. 6 ±4. 0 ) %, ( 13.6 ±1.6 ) %, and ( 72. 4 ± 2. 8 ) %, respectively. IC50 of four cell lines for ADM were 0. 90,0. 92,19. 61 and 4. 04 μg/mL,respectively. Conclusion The data indicate that MDR1 gene stably silenced by lentivirals vector can effectively reverse muhidrug resistance of human breast cancer cells.
出处 《基础医学与临床》 CSCD 北大核心 2008年第2期138-143,共6页 Basic and Clinical Medicine
基金 山东省卫生厅资助项目(2003-138)
关键词 乳腺癌 多药耐药基因1 RNA干扰 慢病毒 breast cancer muhidrug resistance gene 1 (MDRI) RNA interference lentivirus
  • 相关文献

参考文献2

二级参考文献81

  • 1Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 2005; 7: 719-23.
  • 2Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H,Juni A,et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference.Nucleic Acids Res 2004; 32: 936-48.
  • 3Fodorov Y, King A, Anderson E,Karpilow J, Ilsley D, MarshallW,et al. Different delivery methods-different expression profiles.Nat Methods 2005; 2: 241.
  • 4Donze O, Picard D. RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res 2002; 30: e46.
  • 5Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243-7.
  • 6Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P. Lentiviral-mediated RNA interference. Hum Gene Ther 2002;13: 2197-201.
  • 7Druker B J, Talpaz M, Resta DJ,Peng B, Buchdunger E, Ford JM,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
  • 8Barthe C, Gharbi M J, Lagarde V,Chollet C, Cony-Makhoul P,Reiffers J,et al. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br J Haematol 2002; 119:109-11.
  • 9Barthe C, Cony-Makhoul P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy. Science 2001;293: 2163.
  • 10Skorski T, Nieborowska-Skorska M, Nicolaides NC,Szczylik C,Iversen P, Iozzo RV, et al. Suppression of Philadelphial leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1994; 91: 4504-8.

共引文献24

同被引文献13

  • 1王城,金先庆,王佚,肖江卫.P-gp、MRP1、LRP和GST-π在卵黄囊瘤不同组织结构中的表达及临床意义[J].中华小儿外科杂志,2004,25(3):223-226. 被引量:3
  • 2Maria THOMAS,Johann GREIL,Olaf HEIDENREICH.Targeting leukemic fusion proteins with small interfering RNAs:recent advances and therapeutic potentials[J].Acta Pharmacologica Sinica,2006,27(3):273-281. 被引量:11
  • 3Bujons A, Caffaratti J, Pascual M, et al. Testicular Tumours in Infancy and children [ J ]. Actas Urol Esp, 2011, 35:93 -98.
  • 4Hall MD, Handley MD, Gottesman MM. Is resistance use- less multidrug resistance and collateral sensitivity [ J ]. Trends Pharmacol Sci, 2009, 30:546 - 556.
  • 5Treiyer A, Blanc G, Stark E, et al. Prepubertal testicular tumors : frequently overlooked [ J ]. J Pediatr Urol, 2007, 3:480 - 483.
  • 6Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specifie drug binding [J]. Science, 2009, 323:1718-1722.
  • 7Luo Q, Kang Q, Song WX, et al. Selection and validation of optimal siRNA target sites for RNAi-mediated gene si- lencing [ J]. Gene, 2007, 395 : 160 - 169.
  • 8Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application [J]. Nat Rev Drug Discov, 2010, 9:57 -67.
  • 9Shi Z, Liang YJ, Chen ZS, et al. Reversal of MDR1/P- glycoprotein-mediated muhidrug resistance by vector-based RNA interference in vitro and in vivo [J]. Cancer Biol T- her, 2006, 5:39-47.
  • 10肖文静,沈方臻,林明刚.人Bcl-2基因短发夹样RNA真核表达载体的构建和鉴定[J].青岛医药卫生,2009,41(1):5-8. 被引量:2

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部